Verteporfin PDT

DRUG4 trials

Sponsors

QLT Inc., Novartis Pharmaceuticals

Conditions

Age-related Macular DegenerationBasal Cell CarcinomaGorlin SyndromeNevoid Basal Cell Carcinoma SyndromePathological MyopiaPolypoidal Choroidal VasculopathyVisual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Phase 3

Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.

TerminatedNCT00049959

QLT Inc.Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome

End: 2004-03-31Updated: 2011-03-16

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedNCT01217944

Novartis PharmaceuticalsPathological Myopia

Start: 2010-10-31End: 2012-08-31Updated: 2014-02-10

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedNCT01922102

Novartis PharmaceuticalsVisual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Start: 2013-09-11End: 2016-09-14Updated: 2019-06-24

Phase 4

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

CompletedNCT01846273

Novartis PharmaceuticalsAge-related Macular Degeneration, Polypoidal Choroidal Vasculopathy

Start: 2013-08-07End: 2017-03-02Updated: 2019-06-07

Related Papers

Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.

2025-06-12

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study

Ophthalmology and Therapy2024-02-037 citations

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

JAMA Ophthalmology2020-07-16153 citations

Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

JAMA Ophthalmology2017-10-05287 citations